Large Area Mapping at 850 Microns. IV. Analysis of the Clump Distribution in the Orion B South Molecular Cloud

We present results from a survey of a 1300 arcmin^2 region of the Orion B South molecular cloud, including NGC 2024, NGC 2023, and the Horsehead Nebula (B33), obtained using the Submillimetre Common-User Bolometer Array (SCUBA) on the James Clerk Maxwell Telescope. Submillimeter continuum observations at 450 microns and 850 microns are discussed. Using an automated algorithm, 57 discrete emission features (``clumps'') are identified in the 850 micron map. The physical conditions within these clumps are investigated under the assumption that the objects are in quasi-hydrostatic equilibrium. The best fit dust temperature for the clumps is found to be T_d = 18 +/- 4 K, with the exception of those associated with the few known far infrared sources residing in NGC 2024. The latter internally heated sources are found to be much warmer. In the region surrounding NGC 2023, the clump dust temperatures agree with clump gas temperatures determined from molecular line excitation measurements of the CO molecule. The bounding pressure on the clumps lies in the range log(k^-1 P cm^3 K^-1) = 6.1 +/- 0.3. The cumulative mass distribution is steep at the high mass end, as is the stellar Initial Mass Function. The distribution flattens significantly at lower masses, with a turn-over around 3 -- 10 M_sun.Comment: 41 pages, 16 figures, accepted by Ap

Yrast line for weakly interacting trapped bosons

We compute numerically the yrast line for harmonically trapped boson systems with a weak repulsive contact interaction, studying the transition to a vortex state as the angular momentum L increases and approaches N, the number of bosons. The L=N eigenstate is indeed dominated by particles with unit angular momentum, but the state has other significant components beyond the pure vortex configuration. There is a smooth crossover between low and high L with no indication of a quantum phase transition. Most strikingly, the energy and wave function appear to be analytical functions of L over the entire range 2 < L < N. We confirm the structure of low-L states proposed by Mottelson, as mainly single-particle excitations with two or three units of angular momentum.Comment: 9 pages, 3 EPS-figures, uses psfig.st

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

Background & Aims: Hepatitis C virus (HCV) is bound to plasma lipoproteins and circulates as an infectious lipoviral particle (LVP). Experimental evidence indicates that LVPs have decreased susceptibility to antibody-mediated neutralisation and higher infectivity. This study tested the hypothesis that LVPs are required to establish persistent infection, and conversely, low levels of LVP in recent HCV infection increase the probability of spontaneous HCV clearance. Methods: LVP in non-fasting plasma was measured using the concentration of HCV RNA bound to large >100 nm sized lipoproteins after ex vivo addition of a lipid emulsion, that represented the maximum concentration of LVP (maxi-LVP). This method correlated with LVP in fasting plasma measured using iodixanol density gradient ultracentrifugation. Maxi-LVP was measured in a cohort of 180 HCV participants with recent HCV infection and detectable HCV RNA from the Australian Trial in Acute Hepatitis C (ATAHC) and Hepatitis C Incidence and Transmission Study in prison (HITS-p) cohorts. Results: Spontaneous clearance occurred in 15% (27 of 180) of individuals. In adjusted analyses, low plasma maxi-LVP level was independently associated with spontaneous HCV clearance (≤827 IU/ml; adjusted odds ratio 3.98, 95% CI: 1.02, 15.51, P = 0.047), after adjusting for interferon lambda-3 rs8099917 genotype, estimated duration of HCV infection and total HCV RNA level. Conclusions: Maxi-LVP is a biomarker for the maximum concentration of LVP in non-fasting samples. Low maxi-LVP level is an independent predictor of spontaneous clearance of acute HCV

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study

Objective: The objective of the trial was to evaluate in a pilot setting the safety and efficacy of interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a treatment for HIV infection. Design and Setting: This was a multicentre randomised three-arm trial conducted between September 1998 and March 2001 at three clinical centres in the United Kingdom. Participants: Participants were 36 antiretroviral treatment naive HIV-1-infected patients with baseline CD4 T lymphocyte counts of at least 350 cells/mm(3). Interventions: Participants were randomly assigned to receive IL-2 at 15 million international units (MIU) per day ( 12 participants) or 9 MIU/day ( 12 participants) or no treatment ( 12 participants). IL-2 was administered by twice-daily subcutaneous injections for five consecutive days every 8 wk. Outcome Measures: Primary outcome was the change from baseline CD4 T lymphocyte count at 24 wk. Safety and plasma HIV RNA levels were also monitored every 4 wk through 24 wk. The two IL-2 dose groups were combined for the primary analysis. Results: Area under curve (AUC) for change in the mean CD4 T lymphocyte count through 24 wk was 129 cells/mm(3) for those assigned IL-2 ( both dose groups combined) and 13 cells/mm(3) for control participants (95% CI for difference, 51.3 - 181.2 cells/mm(3); p = 0.0009). Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm(3) ( p = 0.008) and 128.4 cells/mm(3) ( p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively. There were no significant differences between the IL-2 (0.13 log(10) copies/ ml) and control (0.09 log(10) copies/ml) groups for AUC of change in plasma HIV RNA over the 24-wk period of follow- up ( 95% CI for difference, - 0.17 to 0.26; p = 0.70). Grade 4 and dose-limiting side effects were in keeping with those previously reported for IL-2 therapy. Conclusions: In participants with HIV infection and baseline CD4 T lymphocyte counts of at least 350 cells/mm(3), intermittent subcutaneous IL-2 without concomitant antiretroviral therapy was well tolerated and produced significant increases in CD4 T lymphocyte counts and did not adversely affect plasma HIV RNA levels

A Structure for Quasars

This paper proposes a simple, empirically derived, unifying structure for the inner regions of quasars. This structure is constructed to explain the broad absorption line (BAL) regions, the narrow `associated' ultraviolet and X-ray warm absorbers (NALs); and is also found to explain the broad emission line regions (BELR), and several scattering features, including a substantial fraction of the broad X-ray Iron-K emission line, and the bi-conical extended narrow emission line region (ENLR) structures seen on large kiloparsec scales in Seyfert images. Small extensions of the model to allow luminosity dependent changes in the structure may explain the UV and X-ray Baldwin effects and the greater prevalence of obscuration in low luminosity AGN.Comment: 35 pages, including 8 color figures (figures 4abc are big). Astrophysical Journal, in press. Expanded version of conference paper astro-ph/000516

Exact solutions for interacting boson systems under rotation

We study a class of interacting, harmonically trapped boson systems at angular momentum L. The Hamiltonian leaves a L-dimensional subspace invariant, and this permits an explicit solution of several eigenstates and energies for a wide class of two-body interactionsComment: 8 pages, error corrected (concerns generalization of subspace structure

The Quantity Theory of Money is Valid. The New Keynesians are Wrong!

We test the quantity theory of money (QTM) using a novel approach and a large new sample. We do not follow the usual approach of first differentiating the logarithm of the Cambridge equation to obtain an equation relating the growth rate of real GDP, the growth rate of money and inflation. These variables must then again be ‘integrated’ by averaging in order to obtain stable relationships. Instead we suggest a much simpler procedure for testing directly the stability of the coefficient of the Cambridge equation. For 125 countries and post-war data we find the coefficient to be surprisingly stable. We do not select for high inflation episodes as was done in most empirical studies; inflation rates do not even appear in our data set. Much work supporting the QTM has been done by economic historians and at the University of Chicago by Milton Friedman and his associates. The QTM was a foundation stone of the monetarist revolution. Subsequently belief in it waned. The currently dominant New Keynesian School, implicitly or explicitly denies the validity of the QTM. We survey this history and argue that the QTM is valid and New Keynesians are wrong

Banks' risk assessment of Swedish SMEs

Building on the literatures on asymmetric information and risk taking, this paper applies conjoint experiments to investigate lending officers' probabilities of supporting credit to established or existing SMEs. Using a sample of 114 Swedish lending officers, we test hypotheses concerning how information on the borrower's ability to repay the loan; alignment of risk preferences; and risk sharing affect their willingness to grant credit. Results suggest that features that reduce the risk to the bank and shift the risk to the borrower have the largest impact. The paper highlights the interaction between factors that influence the credit decision. Implications for SMEs, banks and research are discussed

Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline:a meta-analysis

BACKGROUND: the long-term effect of the use of drugs with anticholinergic activity on cognitive function remains unclear. METHODS: we conducted a systematic review and meta-analysis of the relationship between anticholinergic drugs and risk of dementia, mild cognitive impairment (MCI) and cognitive decline in the older population. We identified studies published between January 2002 and April 2018 with ≥12 weeks follow-up between strongly anticholinergic drug exposure and the study outcome measurement. We pooled adjusted odds ratios (OR) for studies reporting any, and at least short-term (90+ days) or long-term (365+ days) anticholinergic use for dementia and MCI outcomes, and standardised mean differences (SMD) in global cognition test scores for cognitive decline outcomes. Statistical heterogeneity was measured using the I2 statistic and risk of bias using ROBINS-I. RESULTS: twenty-six studies (including 621,548 participants) met our inclusion criteria. 'Any' anticholinergic use was associated with incident dementia (OR 1.20, 95% confidence interval [CI] 1.09-1.32, I2 = 86%). Short-term and long-term use were also associated with incident dementia (OR 1.23, 95% CI 1.17-1.29, I2 = 2%; and OR 1.50, 95% CI 1.22-1.85, I2 = 90%). 'Any' anticholinergic use was associated with cognitive decline (SMD 0.15; 95% CI 0.09-0.21, I2 = 3%) but showed no statistically significant difference for MCI (OR 1.24, 95% CI 0.97-1.59, I2 = 0%). CONCLUSIONS: anticholinergic drug use is associated with increased dementia incidence and cognitive decline in observational studies. However, a causal link cannot yet be inferred, as studies were observational with considerable risk of bias. Stronger evidence from high-quality studies is needed to guide the management of long-term use